Theriva Biologics(TOVX)

1.63-0.12-6.86%

社区社区
资讯资讯
资料资料
公告公告

- 最新
- 推荐
公司概况
公司名称
Theriva Biologics
所属市场
AMEX
成立日期
- -
员工人数
- -
办公地址
- -
公司网址
http://www.therivabio.com
邮政编码
- -
联系电话
- -
联系传真
- -
公司概况
Theriva Biologics, Inc.成立于1986年，是一家生物技术公司，专注于合成DNA为基础的疗法和治疗严重疾病的创新型疾病缓解药物的发展。该公司是一家多元化的临床阶段公司，开发旨在治疗高度未满足需求领域疾病的疗法。公司通过收购VCN Biosciences，SL进入肿瘤学领域，VCN Biosciences，SL开发了一种新的溶瘤腺病毒平台，设计用于静脉、玻璃体内和抗肿瘤递送以触发肿瘤细胞死亡，改善共同给药的癌症疗法对肿瘤的获取，并促进患者免疫系统产生强大而持续的抗肿瘤反应。
- 2024-12-10
  招股说明书
  Form S-1 - General form for registration of securities under the Securities Act of 1933
  Form S-1 - General form for registration of securities under the Securities Act of 1933
- 2024-12-05
  重要事件披露
  Form 8-K - Current report
  Form 8-K - Current report
- 2024-11-20
  员工持股计划
  Form S-8 - Securities to be offered to employees in employee benefit plans
  Form S-8 - Securities to be offered to employees in employee benefit plans
- 2024-11-12
  季度报告
  Form 10-Q - Quarterly report [Sections 13 or 15(d)]
  Form 10-Q - Quarterly report [Sections 13 or 15(d)]
- 2024-11-12
  重要事件披露
  Form 8-K - Current report
  Form 8-K - Current report
- 2024-11-01
  重要事件披露
  Form 8-K - Current report
  Form 8-K - Current report
- 2024-10-16
  重要事件披露
  Form 8-K - Current report
  Form 8-K - Current report
- 2024-10-03
  超过5%披露
  Form SC 13G - Statement of Beneficial Ownership by Certain Investors
  Form SC 13G - Statement of Beneficial Ownership by Certain Investors
- 2024-10-03
  重要事件披露
  Form 8-K - Current report
  Form 8-K - Current report
- 2024-10-02
  超过5%披露
  Form SC 13G - Statement of Beneficial Ownership by Certain Investors
  Form SC 13G - Statement of Beneficial Ownership by Certain Investors
- 2024-09-30
  重要事件披露
  Form 8-K - Current report
  Form 8-K - Current report
- 2024-09-23
  SEC问询函
  Form CORRESP - Correspondence
  Form CORRESP - Correspondence
- 2024-09-23
  [修订]招股说明书
  Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]
  Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]
- 2024-09-23
  重要事件披露
  Form 8-K - Current report
  Form 8-K - Current report
- 2024-09-20
  SEC问询函
  Form CORRESP - Correspondence
  Form CORRESP - Correspondence